STAAR Surgical Company (STAA) Earnings Call Transcript
August 12, 2026
Earnings Call Speaker Segments
Thanks, operator. Hello, everyone, and thanks for being with us this afternoon. Joining today are Warren Foust, who serves as President and Chief Executive Officer of STAAR Surgical, along with Deborah Andrews, Executive Vice President and Chief Financial Officer of STAAR Surgical. We issued our second quarter 2026 results earlier today through a press release in Form 8-K. Our results, the release, and the shareholder letter have all been posted on our investor website at investors.staar.com. This call is set to run for 1 hour and will feature Q&A for publishing analysts. Those joining via webcast may also submit questions for today's Q&A session to ir@staar.com. Before we begin, please note that forward-looking statements will be made during today's discussion. Such statements carry risks and uncertainties that could lead actual results to differ materially from what those forward-looking statements express or imply. I'd urge you to review the disclosures in today's release, as well as in our filings with the SEC. Other than as the law requires, STAAR undertakes no obligation to update these forward-looking statements for future events or actual outcomes. Also, certain non-GAAP financial measures, including adjusted EBITDA and constant currency sales, will be referenced during today's discussion. Definitions and reconciliations of non-GAAP metrics can be found in today's release; to keep things brief, unless stated otherwise, every comparison made on today's call is year over year against the relevant period. One last quick note. Our website is intended to serve as a channel for disclosing material non-public information and for meeting our disclosure obligations under Regulation FD. Those disclosures will appear in the investor relations section of our website. As such, investors should keep an eye on our investor website, in addition to following our press releases, SEC filings, and public conference calls and webcasts. With that, I'll hand the presentation over to our President and CEO, Warren Foust.
Good afternoon, everyone, and thanks for being here with us. Half a year has passed since Deborah and I took on the interim co-CEO positions. When I look back at that period, what stands out is just how much we got done together; we worked through ambiguity and difficult circumstances and embraced major opportunities; and as of today, we can proudly share that the first half revenue results are the best STAAR has ever posted. Within that, we launched EVO Plus in China, which powered share gains and produced growth both year over year and sequentially in that region, consecutive record quarters in the U.S., and a swing back to profitability along with free cash flow generation throughout the business. Those outcomes show the dedication, toughness, and execution of teams everywhere in the company, and that deserves to be celebrated as a milestone. Throughout the whole period, it has been an amazing experience, and I feel thankful for it. Going ahead, I am honored to continue in the role of President and Chief Executive Officer. My thanks go to the Board for trusting me and to all of you for standing by us. Let me pause to acknowledge and express gratitude to Deborah Andrews. During these 6 months, Deborah has been a remarkable partner, dependable, insightful, and unrelenting in what she gives to STAAR. Her sharpness and her emphasis on financial rigor, culture, and strategy have brought deep benefits to this company. I am delighted that she remains our Chief Financial Officer, now also serving as an Executive Vice President. When it comes to leading this company forward, no better partner could be asked for. Now let's turn to the quarter, and it was a solid one. In our shareholder letter that came out today, we cover the second quarter results, how the regions performed, the ERP implementation, and long-term priorities in depth. Instead of going through all of that again here, I would rather concentrate on the 3 priorities we set out close to 6 months back. Growing revenue, expanding profit, and speeding up innovation; all 3 moved forward in the second quarter, and I want to take you through our current position. Beginning with revenue growth, the second quarter delivered strong revenue. Net sales came to $93.5 million, a rise of 111% compared with a year earlier. We achieved sequential growth in China, double-digit growth in the Americas, and double-digit growth in EMEA, leaving out the Middle East. Deborah will walk you through the specifics shortly, but the main takeaway is obvious. This business is performing. There is one key point I want to call out for your modeling. Results for our third quarter of 2025 included recognition of $25.9 million tied to the 2024 order. Consolidated third quarter 2025 net sales were $94.7 million. If you set that item aside, however, the comparable total base comes to $68.8 million; revenue from that 2024 order will not happen again, and when you assess third quarter 2026 year-over-year results, we suggest relying on the adjusted base. Comparisons for the fourth quarter are not affected. Fourth quarter 2025 net sales were $57.8 million; turning now to China, I take pride in our market share gains and in our growing EVO Plus launch. China is still essential to what we're trying to accomplish, and there's a strong opportunity in front of us there. During the quarter, China posted sequential growth, helped along by wider uptake of EVO Plus, and notably, we didn't find any signs that distributors or hospitals were stockpiling inventory, which confirms that demand is what's fueling our growth. The refractive market more broadly is still uneven. Commentary from the industry lately backs up the notion that procedures continue to face pressure in certain parts of China and APAC. Given that environment, STAAR's results reinforce our conviction that EVO is taking share. The EVO Plus rollout is certainly giving us a boost, but beyond that, patients and surgeons are genuinely embracing what lens-based surgery can offer. Folks appreciate that EVO can be reversed and that no corneal tissue has to be removed, and that stands out as a major point of difference while laser-based procedures keep struggling in numerous markets worldwide. We'd also like to shed more light on how seasonality works in China. As we covered in our shareholder letter, the quarterly cadence in China has changed. Q1 and Q2 are now shaping up as our strongest quarters for revenue, lifted by Chinese New Year, an earlier shift of procedures tied to military recruitment, and summer demand. Although Q3 revenue should come in somewhat below Q2 because of the seasonal shifts, if you set aside the one-time order worth $25.9 million that was booked in the third quarter of 2025, we anticipate growth on a year-over-year basis. As usual, Q4 will stay seasonally weaker than the first 3 quarters, yet we're still planning for year-over-year growth. Beyond China, we keep seeing robust revenue contributions from key markets including Japan and Korea, plus double-digit growth in the U.S., the Americas as a whole, and excluding the Middle East and EMEA too; we also see attractive long-term opportunities in plenty of other markets worldwide. Within the Americas, growth was driven by yet another quarter above $6 million in the U.S., marking our second quarter in a row at that level. The U.S. market is still underpenetrated, and we keep seeing room to expand EVO sales and keep capturing share as practices seek differentiated, lens-based refractive options instead of laser vision correction, since demand for laser procedures keeps falling. In APAC outside China, Japan is a key market where EVO enjoys strong category awareness, holds a strong leadership position, and offers sustainable long-term potential; we keep seeing solid underlying demand in Japan, helped by direct-to-consumer awareness efforts kicked off in November of 2025. Unit volume climbed 14%, even though currency headwinds hurt the market and reported sales growth, which landed at 2%. Throughout the wider region, market dynamics differ, and we remain disciplined about where we put our money. In EMEA, excluding the Middle East, the region achieved double-digit growth, mirroring solid underlying demand across much of the area. In every region, our strategy stays the same. Put money where returns are clearest and back surgeons and patients with service, training, and education. As we keep pushing the worldwide move away from laser procedures toward lens-based refractive surgery, we're simultaneously trying to get more product out the door so we can meet rising worldwide demand that has been running ahead of what our supply chain had projected. Profit expansion is the second area. During Q2, we showed substantial headway when it comes to growing profitability; gross profit and net income both rose versus the same quarter a year earlier and versus Q1; those gains produced considerable cash flow, lifting cash to $181.5 million at the close of the second quarter from $163.9 million when the first quarter ended. What this shows is how solid our business model is and the financial rigor Deborah and the team have instilled across the company. The upshot is an organization with robust gross margins, a sturdy balance sheet, zero debt, a growing cash position, and room to put money into the business wherever it counts most — commercial execution, customer support, product availability, innovation, and the systems that help us scale. Throughout the quarter, our ERP rollout called for a great deal of energy and attention from everyone across the organization. And our teams came through. Sales of EVO lenses carried on; we stood behind our customers and posted strong results. That ERP system has gone live, and throughout the third quarter we are busy fine-tuning it. This amounts to more than an operational improvement; it's an investment in our foundation that sharpens visibility throughout the business and sets us up to scale with greater effectiveness and efficiency as we expand. Now that the ERP system is running, we're also starting to lay groundwork for artificial intelligence enabled capabilities that will enhance the way we operate down the line. Innovation acceleration — the third area — is what excites me the most. EVO is a truly differentiated offering, made from our proprietary Collamer material; it's a lens-based procedure that leaves the cornea intact, can be taken out by a surgeon, and treats a wide spectrum of myopia and astigmatism. Although our momentum is considerable and thrilling, and speeding up, our worldwide slice of the refractive market is still well under what we think could be achieved; that shortfall represents our opportunity. Seizing it means outgrowing a one-product approach. EVO, powered by Collamer, serves as our base, yet we can widen things into a larger platform and a more varied product organization, backed by a disciplined innovation roadmap, structured product development, clear milestones, and stronger accountability for execution. Our R&D team, our advanced research group included, is grinding away toward those goals and is getting ready right now for first-in-human studies on the next-generation product we're developing. To bolster these efforts further, we will shortly bring on a chief technology officer to propel STAAR's innovation agenda. I've led that search myself, with help from trusted advisors and our board. And here's my take: this whole process has only made me more convinced about STAAR's potential over the long run. I look forward to sharing additional details in the weeks ahead. We're now entering the next phase for STAAR — Grounded and Differentiated Technology, Disciplined Execution and Sustainable Long-Term Value Creation. So with that said, I'll hand things over to Deborah so she can take us through the financials in greater detail.
Thanks, Warren. I'll give you a quick rundown of the financials, and after that we'll open it up for questions. Net sales for the second quarter came in at $93.5 million, versus $44.3 million in the same quarter a year ago — and just to remind everyone, that prior-year figure took a hit because there were only minimal shipments into China while distributors burned off excess inventory. If you set China aside, net sales reached $41.2 million, which is a 6% increase year over year. Looking at it by region, the quarter tracked pretty closely with the preliminary net sales update we shared back in July. APAC net sales climbed 189% compared with a year earlier. Leaving out China, net sales rose 7% year over year. In China, net sales were up more than 100% and sequential growth came to 10%, bringing the total to $52.3 million; over in Japan, unit volume climbed 14%, but currency headwinds held back reported sales growth, which landed at 2%. The Americas posted 12% growth year over year, and the U.S. turned in another quarter of roughly $6 million. EMEA was down 1%, a result of the ongoing conflicts in the Middle East. If you exclude the Middle East, EMEA grew 12% as well year over year. Gross margin came in at 74.5%, compared with 74% in the same quarter last year. That gain was driven by lower Switzerland ramp-up costs, decreased advanced manufacturing expenses, inventory provisions, and reduced freight and other cost of sales as a share of sales, though it was partly offset by higher per-unit manufacturing costs tied to lower production volumes in 2025. China tariffs on product manufactured in the U.S. also weighed on gross margin. Tariffs will keep pressuring margins until every product we ship to China — 100% of them — is made in Switzerland, and that should be accomplished by the end of 2026. Total operating expenses were $59.6 million, compared with $62.8 million in the same quarter a year ago. If you back out $5.2 million of restructuring and merger related costs from the year-ago period, operating expenses were up roughly 3.7% year over year. Within operating expenses, we had $1.2 million in marketing severance and $1.7 million in ERP consulting; the severance shouldn't recur, and we expect ERP consulting expense to drop significantly starting in the fourth quarter. Depreciation tied to ERP systems was $1.1 million. We're still managing toward our 2026 spending target of $225 million, though we might opt to make targeted investments that push spending marginally higher if the right opportunity comes along. Net income was $8.1 million, or $0.16 per diluted share, versus a net loss of $16.8 million, or $0.34 per diluted share, in the same quarter last year. Adjusted EBITDA came to $20 million, or $0.39 per diluted share, compared with an adjusted EBITDA loss of $14.8 million, or $0.30 per diluted share, in the year-ago quarter. We closed the quarter with $181.5 million in cash, cash equivalents, and investments available for sale, up from $163.9 million at the close of the first quarter, and we still carry no debt. The company currently expects to produce significant free cash flow in the back half of the year, finishing 2026 with well over $200 million in cash. All in all, the second quarter showed meaningful gains in profitability, cash generation, and operating leverage. We're still centered on keeping our finances tight, pushing forward on creating new products, and putting money only into the chances where the payoff looks most obvious. So with that, I'll hand things back over to Warren.
Thanks, Deborah. Looking at the bigger picture, Q2 was a robust period that completed the strongest first-half revenue showing ever for STAAR. That marks one more advance for the company. We increased revenue, widened gross margins, produced net income, and accumulated cash. There's plenty for us to feel good about: rising EVO Plus uptake in China, consecutive record-setting quarters in the U.S., a successful ERP rollout, and initial strides in arranging our product pipeline with the mid- and long-term horizon in mind. Our approach is plain, our people are dedicated and delivering results, and our long-range potential stays just as attractive as it has always been; over 4 million lenses have been sold, we serve 85 countries, and 32 years of demonstrated Collamer safety and efficacy exist in a world growing more myopic annually. At this point, our aim is to capitalize on this momentum. Growing revenue, improving profitability, and pushing innovation forward. Deborah and I are in sync with our board and management team as we concentrate on creating long-term value via well-defined priorities and operational rigor. I appreciate your ongoing backing; with that, operator, let's begin taking questions.
I'd like to focus on Q3, and perhaps get a sense of how you plan to set expectations for investors, especially considering the comparisons and the one-time items that he mentioned. So, taking that adjusted figure of $68.8 million from the press release that he discussed, you know, the consensus right now is at $80.9 million ahead of this report, which is roughly 17.5% growth year-over-year compared to the number you gave. Do you feel good about that consensus figure as it stands? And what would be a solid framework for thinking about the Q3 growth model? If you're not at ease with that figure, how should we approach growth in general for the quarter?
Yes, hey John, excellent question. Good to hear from you, and I'll share a few thoughts and then ask Deborah to come in. Look, we typically don't address consensus figures. What I'd say is we attempted to provide somewhat of a bridge for how to consider Q3 and Q4. We aimed to make it clear that you had to remove the 2024 order from every quarter so you'd have a suitable base. Our goal is to expand from that number; in fact, we're intending to grow in Q4 too. That's our perspective on how to approach it. I believe the main factor behind the success so far, obviously China has rebounded for us. We understand the market is somewhat subdued. You pick that up in some of the remarks from other companies that are reporting, but we think we hold a good edge with EVO Plus launching in that market. We're evidently gaining share against our competitors. And then we're still delivering a strong performance across the rest of the world, even with some external challenges.
All right, excellent; and as a fast follow-up, is there any insight into what portion of China volume EVO Plus represents now compared with what you originally projected when it launched? And how should we consider the balance of price against unit benefit for Q3 in China?
Absolutely. Yeah, that's a fair question. Look, what's taken place with EVO Plus has us thrilled. Honestly, demand has pushed it beyond what our supply can handle. It's come in above our forecast. We definitely observed that during the first quarter, and the second quarter looked the same. So even across other global markets, we're currently trying to figure out how to expand supply so we can meet that demand. That tells you EVO Plus has performed beyond expectations in China. Regarding the penetration percentage, by the time the quarter closed, it's likely near one-third of the units. We consider that fairly robust, and it surpasses our starting assumption. So, thinking about the road ahead in terms of price, we're continuing to command a substantial premium. Neither our customers nor, it appears, their patients have pushed back on that premium. As a result, we anticipate that holding at least for the near term. After that, we'll find out what next year delivers.
I'd like to begin with China, and think about it more over the medium to longer haul. The comp looks odd this year when the street examines the figures, yet clearly you're observing underlying volume growth. You obviously have a solid read on price and mix. So I'm not requesting guidance or anything like that, Warren, but if we look ahead to 2027 on a full-year basis, which clearly removes any quarter-to-quarter seasonality questions, as we sit here right now, what would you consider the general range of, say, normalized year-over-year China growth for STAAR, and then I'll ask a follow-up.
Yes, thanks, Tom. Thanks for the feedback — and honestly, I'm glad you mentioned you're approaching this with a medium-to-long-term view. That's exactly the mindset we're after. Our aim is to build something durable, and that applies not just to top-line results but also to the infrastructure spending we're doing across the company and the groundwork we're laying on the portfolio side. This is a business we plan to operate for many years. So I appreciate that perspective. As you pointed out, setting aside the detail of taking that $25.9 million out of the Q3 base, we'll now be returning to what we refer to as clean quarters. This year has already brought us a couple of solid quarters. In China, the growth you've observed has outpaced the market, and elsewhere globally we've kept delivering. So I don't see any reason that would shift when it comes to China. Here's how we're looking at it: that market is probably growing in the mid to single digits at this point, from a refractive standpoint. Lasers are dragging it down somewhat since they're struggling, but that's being offset by improvements that are largely price-driven — EVO Plus, plus the halo effect from V4c, which kicks in when patients come in asking about V5 and either don't end up with it because its price sits a bit higher on the premium side, or it isn't even available since we're working to meet that demand. So going into next year, that feels like a tailwind to us, though we're not really prepared to say exactly what it will mean quarter by quarter. To wrap up, I want to note that we made an effort to offer additional color—not official guidance, but some sense of how the quarters tend to shape up in China. Over the past couple of years, it's become clear that Q1 and Q2 are now seasonally our strongest periods. Q3 remains solid, though it generally comes in below Q1 and Q2, while Q4 tends to be a softer period in terms of total revenue. That said, we're still expecting growth in both of those quarters, even with the $25.9 million we've discussed at length. Hopefully that clarifies things.
Understood, and thanks for that. For the short term, I may shuffle the order a little. My preference was to start with the longer horizon so the picture would be clearer, but instead I'll try the 3Q, 4Q sequence and focus on China. Warren, assuming I caught it right, I think you mentioned that China revenue in 3Q would come in somewhat below 2Q. I'm hoping that's what I heard. What I'd like to know is whether we can put a finer point on it. And I'll ask about it by referencing 3Q24 and 3Q23. In China, the dollar decreases were about $10 to $15 million. Warren or Deborah, for 3Q26 in China, would that still be a sensible way to look at it — particularly given that EVO Plus Mix, as I understand it, continues to create a sequential headwind; and when we consider what sounds like fairly resilient ICL China summer high season momentum. So is that $10 to $15 million decline you've referenced previously a good solid anchor point?
Yes, that's a good one. Look, I'll start and then bring in Deborah. I think two things are important to keep in mind. The seasonal shift I described has occurred. So Q1 and Q2, we expect to be stronger. Part of that is pulled forward from the third quarter. So it's tough for us to sit here and say with certainty exactly what will play out in Q3, first because of that timing effect, and second because of the point we made about needing to move some 2024 orders out of Q3. Even so, we continue to expect — and I think this is the key part — that underlying demand in China is steady. It isn't spectacular. It isn't as strong as during the hypergrowth days, but we're benefiting from it more than our fair share, in our view, thanks to faster share gains. So that's the way I'd frame it. Figuring out an exact figure there is tough for us, and that pretty much explains the reason it exists.
Congrats to everyone on the new roles, and I can't wait to work with all of you as we move ahead. Maybe I'll start with the U.S., then come back to China. Perhaps a brief status on active sites and the approach behind it. So where are we on the overall count of active sites in the U.S.? I understand there was, in effect, a go-deeper penetration strategy, but there was also a push to add new sites. Could you bring us up to date on the present active site tally, and also give us a refresher on how you're striking a balance between going deeper at existing EVO live locations and bringing new accounts on board? Then I've got a China question.
Absolutely, Anthony, thanks — great to hear from you. What we see in the U.S. lines up broadly with what's going on across the globe. Keep in mind, EVO was only approved back in 2022. The commercial launch essentially took place in 2023, and throughout that stretch we were still building out the team. So what you see now is our active sites sitting in the hundreds and hundreds and hundreds. We're ramping up in places where we feel sure we can deliver the biggest impact. Two primary priorities guide us; though this discussion is U.S.-focused, that same logic applies internationally. To be specific, once customers build clinical confidence, after they've used EVO and those patients return for visits with the clinic or the optometrist, you've got happy people. What we observe is that as surgeons become more clinically confident, the next thing they ask is how to make this economically workable for themselves. The response differs depending on whether they do procedures within their own practice or whether they get in their car and drive to a multi-specialty ASC, where they have to pay somewhere between $900 and $1,800 per eye to perform the surgery. That situation is tougher than when in-office suites are available, where a physician can just walk down the corridor and operate inside his or her own practice. So you can see how each of those scenarios carries its own opportunities. We've segmented those customers. We're pursuing clinically confident customers aggressively and with a business case: you're losing revenue because high-diopter patients are walking away from your practice, and at the same time someone's pitching them LASIK, which is down year over year and now down again quarter over quarter. Frankly, that pitch feels nearly obsolete by now, since these days patients show up requesting EVO themselves because they keep hearing about it. Younger patients, and younger doctors as well, recognize the value in a technology you can remove and reverse, so excitement runs higher — which means a rising number of U.S. surgeons now offer EVO among the refractive options they provide. The adoption is clearly picking up — walkout revenue is declining, and a growing number of the practices we're targeting are narrowing that price gap for patients, which puts treatment more within their reach, and that's what we see driving uptake here in the U.S. Even though volume remains under where we'd want it, we're happy to post another quarter at $6 million, and we're keen for that growth to continue, with 2022 underway.
That's really useful. Regarding China and EVO Plus, can you remind us what share of the market the bigger lens size unlocks there? Also, looking at consignment figures, they've risen quite a lot versus a year ago in the queue. How much of China consignment sales tied back to EVO Plus?
Deborah can address the consignment sales. On the opportunity side, from our view, market demand has no ceiling — not only in China but worldwide. Refractive error that goes untreated across the globe is enormous. So we're pursuing that. Naturally, certain factors hold us back; total patients entering the refractive market and booking consultations limits us. As for EVO Plus in China, inventory has been a bit of a constraint since we've had trouble producing sufficient volume for Q1 demand and then Q2. I believe we're now getting a handle on it, especially entering the later portion of Q3 and moving into Q4, when seasonality dynamics will cause some demand to ease. That should actually benefit us on the supply side. But what you're observing is, EVO Plus doesn't bring in any extra patients, since it works for the same patient set as EVO. At the account level it's a premium positioning question, and whether the patient's economics can sustain it.
Okay, this is Deborah speaking. If we look at it from a consignment perspective, our consignments in China have dropped significantly. That's the reason you're noticing higher tariff expenses affecting gross margin. As you may remember, we sent those consignments out prior to the higher tariffs taking effect last year, in early last year. So at this point, with those lenses having been consumed, we're increasingly shipping U.S. product into China, and tariffs apply to them. Still, the total figures for China consignments are way down.
Warren, you described the share gains in China as mostly driven by procedures using lasers. Could you walk us through how that's actually working? Is it that more patients are choosing ICL right away, or is the larger factor that surgeons are adding ICL to their offerings and shifting cases over within their own practices? And with local rivals emerging in China's refractive space across the coming few years, how sustainable do you think those share gains will prove to be?
Yeah, hey, Simran. Appreciate the question. Look, let's take competition first — we're delighted to have competitors; it mostly serves as a reminder that from a refractive surgery perspective, the future belongs to lens-based approaches. You're watching laser volumes worldwide run into headwinds. And is that what's going on in China? Hard to say once we get into the share discussion. Our view is that some of each is taking place. Patients show up requesting EVO Plus. Frequently, they receive EVO Plus when they've got the financial means for it and we can provide it. And then even in cases where they don't and when someone qualifies for V4c, we observe somewhat of a halo effect emerging there. So even with refractive market growth in China being otherwise fairly modest, our belief is that we're capturing a larger portion of it, since we're gaining dollar share through EVO Plus and likely picking up some unit share with EVO Plus and with EVO, which is what's drawing in that competition. And so, we hold it in respect. We observe it beyond China. We observe it within China; up to now it hasn't made much of an impact. Keep in mind, these are acrylic lenses. What gives STAAR an edge for 32 years and counting now is our material. The message that EVO and EVO Plus are powered by Collamer is quite genuine, and the confidence our surgeons place in a device they've implanted for more than 30 years gives them tremendous assurance, and I believe that makes it harder for these competing devices that aren't built from Collamer to go head-to-head in those markets. That isn't to say we lack respect for them, it simply means they face an uphill battle.
Understood, that's really useful. And for my next question — outside China, I definitely see that each region posted year-over-year gains, but when I look at how APAC specifically has been trending, the pace seems to have slowed quite a lot. So perhaps you could walk us through what's happening there, and more generally, should we view ex-China as roughly a mid-single-digit grower moving forward, or could that growth rate pick back up?
You know, in APAC we're getting solid contributions from our biggest markets there — Japan and Korea. On a unit basis Japan rose considerably, yet ran into huge currency and exchange-related headwinds; so even in units I believe that's 13% or 14% growth, and once currency hit, we were left with only 2% growth. From that angle it's modest, though the market activity underneath remains robust. And nothing leads us to expect that to shift. Korea is somewhat in its low season. Korea is also smaller than Japan, but it matters a great deal to us, and it's onewcastlemax where our sales execution is excellent and our customer relationships are strong, so we have faith in that market's long-term viability too. India is truly a long-term play for us; that market is complicated; it's complicated when it comes to local competition. It's complicated when it comes to the macroeconomic factors they face. Obviously there are currency issues tied to being able to access U.S.-made and Swiss-made products in India. So for us that's a long-term process, but it remains a really important market; so regarding the core of your question about what growth rate we should expect, I can't say, but what I would say is we see no reason to believe that EVO's viability in those markets will be under any siege.
Right, I simply wanted to mention as well that we're experiencing quite impressive expansion in Taiwan, a market we only introduced in the last year. And that territory is performing extremely well indeed. Each quarter, on a sequential basis, it has grown considerably. So it's a good market there.
This is an enjoyable market to consider, since EVO Plus just received approval. Clearly, it sits next to China. Consequently, regarding the patient population, they can reach and observe social media along with the satisfaction associated with EVO. Moreover, this is the one we will begin servicing, and it is packed with lasers and opportunity.
So, first off, let's revisit for a moment how pricing and volume are behaving in China. Warren, what you said regarding EVO Plus accounting for one-third of lenses there really caught my attention. Suppose there's a 30% to 40% premium in price on that item — by my reckoning, that implies roughly 10 points of growth coming from those lenses. Yet strip that away, with everything else held constant, and if China's market is growing at a mid-single-digit pace — and yes, I recognize you're gaining share there — wouldn't that mean units, the volumes themselves, are actually shrinking in China?
Well, you have to begin from the exit share in July. For the entire year, EVO Plus isn't a third of units. Keep in mind, we're ramping up gradually. We haven't even introduced EVO Plus across all the hospitals or the systems where we'll eventually be launched and listed. So from that angle, the math gets somewhat tricky. Still, I'll simply emphasize that revenue in China today is powered by 2 factors: one is the comeback of our EVO V4c, which brings something of a halo effect, and the other is uptake — both in units and in price — with EVO. As for how far that goes from a one-third exit figure to the full year, we'll find out. That's still unknown, and we also need to be capable of supplying it.
Alright, that's quite useful and it clears things up. My next question is about the U.S. And once more, I understand that this is still ramping, but looking back at when EVO came to market in the U.S., we've witnessed quarter-over-quarter gains from Q1 to Q2 in each period since that launch. I recognize it's flat at $6 million, yet it slipped sequentially somewhat in the U.S. during Q2. That could simply reflect, you know, modest figures and similar factors. Still, I wanted to hear your take on it, since it remains early, given what's possible in the U.S.
Good question. Look, I believe the U.S. market's value over the long haul is enormous. I think the access we've got will give us a pathway to accomplish all kinds of things. This is a long-term conversation, not something measured quarter by quarter. But practically speaking, despite the fact that we outperform the laser market, frequently there's an inverse link between the laser market's decline and our growth, yet we clearly aren't capturing all of those points lost by them. So whenever the total refractive market contracts or expands, we gain from it or we endure a little; thus in Q2, compared with Q1 on a sequential basis, you observed the laser, the entire refractive market drop, pulled down by lasers since they hold the dominant portion, And so we took a bit of a hit from that. That accounts, I believe, for part of the sequential, we expanded yet the decrease relative to our Q1 result, which was around 22%. There's likely some timing involved as well. Then another point I'll state frankly, the U.S. accounts for 5%, perhaps 7% of the share here. Whenever we face backorder or supply limitations in our biggest market, China, or elsewhere as a consequence, as we attempt to meet demand by manufacturing product, we must produce MTOs, made-to-order items for Torics. And when we do so, those get made in lesser units, a reduced volume of units, and so it clogs our supply chain; and when that occurs, what do you know? The U.S. ends up on back order for MTOs. That will account for part of it as well. I'd guess if you check with customers, you'll discover some dissatisfied ones, regrettably, in the U.S. who are attempting to obtain product from us, which we're now producing rapidly to catch up.
Perhaps regarding the ERP, is there a way to put a figure on how it affected second quarter earnings—sorry, orders or revenue—and will all of that be made up during the third quarter, or does it take more time, or by now is it simply sales that are gone?
No, no, in our view there wasn't a material effect, no material effect at all on our revenue figures. When it comes to the P&L, the effect fell mostly on expenses, since we were working to stabilize the whole system and to upgrade or update it. On the revenue side, though, there may have been some sales that were lost, I suppose, on the MTO portion, the made-to-order lens portion. That's possible. Yet that is mostly caused not by the ERP system. What causes it is the strong demand during the first half of the year, particularly in China.
David, this topic came up during the pre-release as well as in the shareholder letter. Frankly, what we're mainly doing is acknowledging the tremendous effort put in by our teams — despite the internal strain involved, we kept shipping products, kept booking orders, kept servicing customers, and kept bringing in the quarter's revenue, which is what produced our profit. So in my view, the ERP system has been a major undertaking. We'll keep refining it moving forward, but as far as revenue goes, I'd say the effect was negligible.
Yeah, I mean, I'd just point out that in fact we've gone past what we set out to do — our operating plans — for Q1 and Q2 of this year. That's what I'd say; on the whole, we're happy.
All right, that's useful. I appreciate it. Let me attempt a question about the third quarter as well. Clearly, I hear what you're saying about seasonality. So, in rough figures for Q3, it sounds like the outcome will fall between $70 and $90 million. Given that we're roughly midway through that quarter, how would you describe the pattern we're seeing from one period to the next? How sharp or slow does that trajectory appear right now?
Well, I'm not going to get into details on that. From the perspective of a trajectory, my sense is not much has shifted; there's been some discussion circulating regarding the peak period in China, and as we recall, there appear to be two peak periods occurring consecutively across Q1 and Q2, driven by the earlier timing of the military procedures plus the Chinese New Year. Then during the second quarter, you receive part of the summer peak period, which diminishes over the course of Q3. If you follow what's going on in China, the market there is expanding at something like flat to mid-single digit rates; and as we've told you before, at least during that quarter, our performance exceeded that. So assuming all of those factors continue as we move ahead, you simply need to subtract the $25.9 million from the prior quarter to arrive at your Q3 figure and consider a modest amount of growth there. The same applies to Q4. That order had no impact on Q4, but our plan is at minimum to achieve growth in Q4.
This is Harrison filling in for Mason. I just had a question about ASPs — blended ASPs are getting squeezed by the Toric/sphere mix as well as the diopter curve dynamics. Once we finished Q2 with China volume at 30%, is the EVO Plus premium big enough now to counteract those headwinds at the consolidated level for the second half of the year?
Well, that's a fair question. To land on the best response, I'd need to spend quite a bit of time thinking it through. What I'd say is that obviously we will keep working to bring ASP up to whatever level allows us to benefit from an EVO Plus tailwind. That said, price depends on — at least in Europe, in a country such as Germany, where our price is the highest across Europe — the fact that we're up against competition means we'll see some ASP slippage there, though it isn't huge; across most markets worldwide we've kept price steady, in part because Toric adoption keeps growing, and Toric carries a somewhat higher price, so the greater our Toric mix, the stronger our pricing, which is why pricing worries me less, while what I care about more, and where my attention goes, is staying on course to keep gaining share, and we think we have line of sight to keep doing that. So instead of claiming we'll offset price erosion through price in China on EVO Plus, I'd put it this way: our focus is on gaining share in global markets, and we think that's achievable. You brought up diopter — outside China, looking at the percentage of units we sell, if you consider above minus 8 and below minus 8, we've shifted downward outside China by a couple of percentage points at minimum, from minus 8 into the minus 6 to minus 8 range. So we believe we keep moving further down the diopter curve. Whenever we do that, it creates a chance to gain share where lasers might previously have been the treatment for that patient; that, rather than the ASP piece, is where our focus will be.
Excellent, thanks. That clears things up. Apologies in advance if this was already covered earlier on the call, but at what point do you think there will be sufficient EVO Plus stock on hand to completely meet the demand you're currently observing in the China region?
Well, my sense is we're basically at that point now, or close to it. Keep in mind that the summer portion of the peak season will soon begin winding down, which hands us an opportunity to pause and catch up on building units. So roughly by the time the third quarter wraps up, I believe we'll be positioned to provide however much EVO Plus is needed. At this stage, our priority is producing V4c. Don't forget, each V4c unit we manufacture in Switzerland destined for China means we avoid paying the tariffs. So while supplying EVO Plus is our focus, there's a secondary objective of making sure we get as much V4c as possible shipped out of China; and our hope is that by year's end we'll manage to get that done.
Nice work on those appointments. I'll limit myself to a single question with several parts. In the press release, you mentioned going past being a company with just one product line and becoming what I believe you called a genuine platform. Can you elaborate on that? Does that mean you're looking at expanding outside refractive? Or does it really mean concentrating on providing a wider range of options inside refractive? And my assumption is that everything begins and ends with your polymer-based technology. Is that the correct way to view it? Also, whatever you can say about possible timelines — whether we're talking years, or the medium to long term — would be useful.
Thank you, Adam. That's a question I really enjoy. Here's the thing: we're eager to operate this business over the long haul. Our thinking has genuinely shifted to this point — we aim to build the infrastructure and the capabilities so that this becomes a long-term investment for people, and a long-term successful ophthalmology company. So when it comes to pipeline, we have excellent engineers, plus excellent clinical, medical, and regulatory talent within this organization, and they've been quietly working for years on many different things. We look forward to uniting those efforts into a portfolio that's more cohesive and easier to grasp. Future releases will cover that. Today we aren't prepared to discuss it. You've heard us mention that a chief technology officer will be hired. That excites me. I'm also excited to finally be able to discuss first in human testing, which we'll conduct very soon — possibly as early as the first part of next year, or maybe even sooner if we can manage it. That concerns next generation products. As we've stated previously, our focus is on things that are, naturally, extremely, extremely important. The material capabilities we possess are unique. That's the reason Collamer has set us apart for many years. So we intend to apply those same capabilities — be it Collamer or be it something else — so we can accelerate and become more than merely an EVO ICL company. Refractive is our wheelhouse. In the sulcus is our wheelhouse, where surgeons put the EVO ICL. So all of those, I believe, represent opportunities. In the past you've heard us discuss extended depth of focus or presbyopia correction — being able to leverage a patient's natural ability to accommodate, yet give them some additional help via a lens-based technology — and that's one option among many others. So as we proceed, we'll discuss those more formally, but there's plenty of excitement here regarding our future.
I'll stay tuned. Thank you.
Kindly remain on the line while we open things up for questions. With no more questions coming in, that brings both our Q&A portion and this conference call to a close. We appreciate your participation in today's presentation. You're welcome to disconnect at this time.
Read the full transcript via the API
You're viewing the first half of this call. Get the complete STAAR Surgical Company transcript - plus 132,000+ transcripts from 7,000+ companies, speaker segments and full-text search - through the EarningsAPI REST API or hosted MCP server.
Get an API key View API docs →For developers and AI pipelines
Programmatic access to STAAR Surgical Company earnings transcripts and 132,000+ others is available through the
EarningsAPI REST API and the hosted MCP server.
Quarterly plans from $162 - full transcripts, speaker segments, full-text search,
and the /api/v1/transcripts/recent polling endpoint for ETL pipelines.